FF-10502, an Antimetabolite with Novel Activity on Dormant Cells, Is Superior to Gemcitabine for Targeting Pancreatic Cancer Cells-Reference-Cited by-同舟云学术

FF-10502, an Antimetabolite with Novel Activity on Dormant Cells, Is Superior to Gemcitabine for Targeting Pancreatic Cancer Cells

Published:2018-04-13 Issue:1 Volume:366 Page:125-135
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Mima Shinji,Kakinuma Chihaya,Higuchi Tamami,Saeki Kazunori,Yamada Takayuki,Uematsu Rena,Ishino Miki,Kito Nobuko,Nishikawa Hiroki,Kuniyoshi Hidenobu,Matsumoto Takuya,Fujiwara Hideyasu,Paradiso Linda J.,Shimada Yasuhiro,Iwamura Hiroyuki

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference37 articles.

1. The time of occurrence of liver metastasis in carcinoma of the pancreas;Amikura;Int J Pancreatol,1995

2. Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer

3. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;J Clin Oncol,1997

4. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

5. Multicellular tumor spheroid model to evaluate spatio-temporal dynamics effect of chemotherapeutics: application to the gemcitabine/CHK1 inhibitor combination in pancreatic cancer

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF‐10502‐01 for the treatment of advanced solid tumors;Cancer;2023-03-07

2. A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models;Pharmaceutical Research;2021-05-07

3. F-aza-T-dCyd (NSC801845), a Novel Cytidine Analog, in Comparative Cell Culture and Xenograft Studies with the Clinical Candidates T-dCyd, F-T-dCyd, and Aza-T-dCyd;Molecular Cancer Therapeutics;2021-04

4. Tumor Cell Dormancy: Threat or Opportunity in the Fight against Cancer;Cancers;2019-08-19